Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J O'Neill

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Oncotarget|October 13, 2016
Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cellsIan R Logan, Urszula L McClurg, Dominic L Jones, et al.
Epigenetics|April 23, 2014
SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cellsDaniel J O'Neill, Stuart Charles Williamson, Dhuha Alkharaif, et al.
Molecular Cancer Research : MCR|September 30, 2024
Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate CancerLaura Walker, Ruaridh Duncan, Beth Adamson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2023
Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain BarrierNicola Colclough, Ravindra V Alluri, James W Tucker, et al.
ACS Medicinal Chemistry Letters|September 19, 2019
Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET InhibitorsGavin W Collie, Cheryl M Koh, Daniel J O'Neill, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Communications Biology|April 24, 2024
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancerMatthias Pfeifer, Jonathan S Brammeld, Stacey Price, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Oncotarget|October 13, 2016
Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cellsIan R Logan, Urszula L McClurg, Dominic L Jones, et al.
Epigenetics|April 23, 2014
SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cellsDaniel J O'Neill, Stuart Charles Williamson, Dhuha Alkharaif, et al.
Molecular Cancer Research : MCR|September 30, 2024
Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate CancerLaura Walker, Ruaridh Duncan, Beth Adamson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 10, 2023
Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain BarrierNicola Colclough, Ravindra V Alluri, James W Tucker, et al.
ACS Medicinal Chemistry Letters|September 19, 2019
Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET InhibitorsGavin W Collie, Cheryl M Koh, Daniel J O'Neill, et al.
Molecular Cancer Therapeutics|February 28, 2018
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc'h, Matthew J Martin, Jonathan W Riess, et al.
Communications Biology|April 24, 2024
Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancerMatthias Pfeifer, Jonathan S Brammeld, Stacey Price, et al.
Journal of Medicinal Chemistry|June 21, 2023
Discovery and Optimization of the First ATP Competitive Type-III c-MET InhibitorIacovos N Michaelides, Gavin W Collie, Ulf Börjesson, et al.
Pageof 1